Clinical Use of Cisplatin Liposomes for Patients With Refractory Advanced Cancer.

Yasuo Komura, Shintarou Kimura, Tomoko Katagiri, Yuumi Hirasawa, Hiromi Muranishi, Koichiro Homma

Abstract readCase Reports

In one paragraph

Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yasuo KomuraInternal Medicine, Rinku Medical Clinic Advanced Medical Center, Osaka, JPN.

Shintarou KimuraEnvironmental Science, StateArt, Inc., Tokyo, JPN.

Tomoko KatagiriResearch and Development, StateArt, Inc., Tokyo, JPN.

Yuumi HirasawaMedical Technology, StateArt, Inc., Tokyo, JPN.

Hiromi MuranishiInternal Medicine, Kyotooike Medical Clinic, Kyoto, JPN.

Koichiro HommaEmergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, JPN.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study aimed to evaluate the safety and efficacy of cisplatin (CDDP) liposomes. A patient with multiple recurrent liver metastases from metastatic nasal carcinoma was administered CDDP liposomes with consent. Magnetic resonance imaging showed that the patient remained stable disease; however, no apparent side effects were observed, and blood draw data showed no worsening of renal function. Patients undergoing partial pancreatectomy and jejunoileal biliary anastomosis for biliary tract cancer who consented to receive CDDP liposomes demonstrated a partial response on angiographic computed tomography; however, they showed slight fatigue. To our knowledge, the present study is the first in Japan to suggest that liposomalization of CDDP may have anticancer effects while alleviating renal damage and bone marrow suppression.

Indexed as

adverse drug reactioncirculating tumor cellscisplatin liposomesenhanced permeability and retention effectnephrotoxicitypulmonary metastasis of pancreatic cancerquality of liferecurrent liver metastases from primary nasal cancer

Identifiers

PMID39650995

DOI10.7759/cureus.73181

PMCPMC11624460

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.